Press Releases

Follow our journey to bring our immune-modulation products to patients


October 29, 2019

Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine

more
October 1, 2019

Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial

more
September 18, 2019

Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline

more
August 22, 2019

Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates

more
June 4, 2019

CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development

more
February 25, 2019

Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate

more
November 5, 2018

Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet

more
October 11, 2018

Themis Bioscience Announces Exclusive Licensing Agreement with Max- Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies

more
June 11, 2018

Themis Receives EMA PRIME Designation for Chikungunya Vaccine

more
March 7, 2018

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

more
February 26, 2018

Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

more
January 4, 2018

Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline

more